KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Short term Debt: 2013-2022

Historic Short term Debt for TherapeuticsMD (TXMD) over the last 2 years, with Sep 2022 value amounting to $93.6 million.

  • TherapeuticsMD's Short term Debt rose 524.01% to $93.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $93.6 million, marking a year-over-year increase of 524.01%. This contributed to the annual value of $188.3 million for FY2021, which is N/A change from last year.
  • As of Q3 2022, TherapeuticsMD's Short term Debt stood at $93.6 million, which was up 3.11% from $90.8 million recorded in Q2 2022.
  • TherapeuticsMD's Short term Debt's 5-year high stood at $202.9 million during Q1 2022, with a 5-year trough of $5.0 million in Q1 2021.
  • For the 2-year period, TherapeuticsMD's Short term Debt averaged around $86.5 million, with its median value being $90.8 million (2022).
  • Data for TherapeuticsMD's Short term Debt shows a peak YoY soared of 3,957.14% (in 2022) over the last 5 years.
  • TherapeuticsMD's Short term Debt (Quarterly) stood at $188.3 million in 2021, then skyrocketed by 524.01% to $93.6 million in 2022.
  • Its Short term Debt stands at $93.6 million for Q3 2022, versus $90.8 million for Q2 2022 and $202.9 million for Q1 2022.